candesartan has been researched along with Atrophy in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "With candesartan-based treatment, compared with control, the relative risk of non-fatal stroke was 0." | 2.43 | The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses. ( Trenkwalder, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuruya, K | 1 |
| Yoshida, H | 1 |
| Trenkwalder, P | 1 |
1 review available for candesartan and Atrophy
| Article | Year |
|---|---|
The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrophy; Benzimidazoles; Bip | 2006 |
1 other study available for candesartan and Atrophy
| Article | Year |
|---|---|
Brain Atrophy and Cognitive Impairment in Chronic Kidney Disease.
Topics: Animals; Atrophy; Benzimidazoles; Biphenyl Compounds; Brain; Cognitive Dysfunction; Cyclic N-Oxides; | 2018 |